The College of Oxford has launched a examine to evaluate the protection and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in youngsters for the primary time, it mentioned on Saturday.
The brand new mid-stage trial will decide whether or not the vaccine is efficient on folks between the ages of 6 and 17, in accordance with an emailed assertion from the college.
Round 300 volunteers can be enrolled and first inoculations are anticipated this month, Oxford mentioned.
Resort quarantine for travellers to start Feb. 22, Trudeau says
Surgeon saves ‘Gorilla Glue woman’ who sealed her hair with superglue
AstraZeneca vaccine ‘not excellent’ however will save 1000’s of lives, CEO says
The 2-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ as a result of it’s cheaper and simpler to distribute than some rivals.
AstraZeneca has a goal to supply 3 billion doses this yr and goals to supply over 200 million doses per 30 days by April.
Canada has but to approve AstraZeneca’s vaccine.
As of Feb. 12, folks below the age of 19 accounted for 16.5 per cent of instances (133,794) all through the nation, in accordance with Well being Canada.